ACTRN12605000594628RecruitingNot Applicable
A pilot study to evaluate the feasibility, safety and efficacy of psychotherapeutic intervention for comorbid BPD and first-episode psychosis
Orygen Research Centre and Orygen Youth Health0 sites16 target enrollmentStarted: October 5, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 16
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 15 Years to 25 Years (—)
- Sex
- All
Inclusion Criteria
- •(1) Eligibility for EPPIC program, 1 week or more of psychotic symptoms with less than 6 months of active previous treatment (i.e., antipsychotic medication); and (2) Diagnosis of four or more DSM-IV BPD traits (APA, 1994).
Exclusion Criteria
- •(1) Severe and enduring psychotic symptoms, defined as scores of 4 or more on 1 or more psychotic items of the Brief Psychiatric Rating Scale (BPRS) which have persisted for more than 1 month (Overall & Gorham, 1962); (2)Unable to converse in, or read English without an interpreter; (3) Intellectual deficits, such that unable to meaningfully participate in the psychotherapy; and (4) Already given informed consent for another psychotherapy trial at ORYGEN Youth Health, or already received a course of CAT.
Investigators
Similar Trials
Not yet recruiting
Phase 2
A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomyCancer - ProstateProstate cancerACTRN12607000082404rology Department The Royal Melbourne Hospital15
Recruiting
Phase 1
A pilot study of patients with oligometastases from breast cancer treated with stereotactic ablative body radiosurgery in combination with the anti-PD-1 antibody MK-3475.Metastatic Breast Cancer (1-5 metastases)Cancer - BreastCancer - BoneACTRN12614001181695Peter MacCallum Cancer Centre15
Recruiting
Not Applicable
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using Indocyanine green.NL-OMON24349Meander Medical Centre, Department of Surgery10
Active, not recruiting
Phase 1
Identification of the sentinel lymph node (SLN) in patients with colon carcinoma.Colon carcinomaEUCTR2021-006796-41-NLMeander Medical Centre5
Completed
Not Applicable
A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CWcolon carcinomaintestinal cancer1001799010017991NL-OMON53524Meander Medisch Centrum5